153 related articles for article (PubMed ID: 8471420)
41. An evaluation of five different methods for estimating proliferation in human colorectal adenocarcinomas.
Wilson MS; Anderson E; Bell JC; Pearson JM; Haboubi NY; James RD; Schofield PF
Surg Oncol; 1994 Oct; 3(5):263-73. PubMed ID: 7889219
[TBL] [Abstract][Full Text] [Related]
42. First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR.
Rebischung C; Hoffmann D; Stefani L; Desruet MD; Wang K; Adelstein SJ; Artignan X; Vincent F; Gauchez AS; Zhang H; Fagret D; Vuillez J; Kassis AI; Balosso J
Int J Radiat Biol; 2008 Dec; 84(12):1123-9. PubMed ID: 19061137
[TBL] [Abstract][Full Text] [Related]
43. In vivo uptake of 131I-5-iodo-2-deoxyuridine by malignant tumours in man.
Philip PA; Bagshawe KD; Searle F; Green AJ; Begent RH; Newlands ES; Rustin GJ; Adam T
Br J Cancer; 1991 Jan; 63(1):134-5. PubMed ID: 1989652
[No Abstract] [Full Text] [Related]
44. 5-[125]iodo-2'-deoxyuridine in the radiotherapy of solid CNS tumors in rats.
Kassis AI; Adelstein SJ
Acta Oncol; 1996; 35(7):935-9. PubMed ID: 9004774
[TBL] [Abstract][Full Text] [Related]
45. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Gandhi V; Plunkett W; Kantarjian H; Talpaz M; Robertson LE; O'Brien S
J Clin Oncol; 1998 Jul; 16(7):2321-31. PubMed ID: 9667246
[TBL] [Abstract][Full Text] [Related]
46. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
[TBL] [Abstract][Full Text] [Related]
47. Synchronization of hepatocellular DNA synthesis in regenerating rat liver by continuous infusion of hydroxyurea.
Rabes HM; Iseler G; Czichos S; Tuczek HV
Cancer Res; 1977 Apr; 37(4):1105-11. PubMed ID: 844040
[TBL] [Abstract][Full Text] [Related]
48. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
49. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
50. The use of 5-(125I)iodo-2'-deoxyuridine for monitoring DNA synthesis in organ culture.
Riches AC; Gore D; Docherty J; Littlewood V
J Anat; 1976 Apr; 121(Pt 2):323-9. PubMed ID: 58855
[TBL] [Abstract][Full Text] [Related]
51. The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells.
Kuo ML; Kunugi KA; Lindstrom MJ; Kinsella TJ
Cancer Res; 1995 Jul; 55(13):2800-5. PubMed ID: 7796406
[TBL] [Abstract][Full Text] [Related]
52. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
[TBL] [Abstract][Full Text] [Related]
53. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization.
Belt RJ; Haas CD; Kennedy J; Taylor S
Cancer; 1980 Aug; 46(3):455-62. PubMed ID: 7397621
[TBL] [Abstract][Full Text] [Related]
54. The clinical rationale for S-phase radiosensitization in human tumors.
McGinn CJ; Kinsella TJ
Curr Probl Cancer; 1993; 17(5):273-321. PubMed ID: 8281809
[TBL] [Abstract][Full Text] [Related]
55. Preparation and preliminary evaluation of novel beta-cyclodextrin/IUDR prodrug formulations.
Wiebe LI; Yang XH; Singh S; Diakur J
J Pharm Pharm Sci; 2008 Jun; 11(2):32s-43s. PubMed ID: 19203469
[TBL] [Abstract][Full Text] [Related]
56. Probabilistic modeling of DNA mismatch repair effects on cell cycle dynamics and iododeoxyuridine-DNA incorporation.
Gurkan E; Schupp JE; Aziz MA; Kinsella TJ; Loparo KA
Cancer Res; 2007 Nov; 67(22):10993-1000. PubMed ID: 18006845
[TBL] [Abstract][Full Text] [Related]
57. Cell-cycle-dependent and -independent damage to rat haemopoiesis by hydroxyurea.
Dörmer P; Böhmer RM
Cell Tissue Kinet; 1984 Nov; 17(6):619-28. PubMed ID: 6488279
[TBL] [Abstract][Full Text] [Related]
58. Radioiododeoxyuridine in cancer therapy: an in vitro approach to developing in vivo strategies.
Schneiderman MH; Schneiderman GS
J Nucl Med; 1996 Apr; 37(4 Suppl):6S-9S. PubMed ID: 8676203
[TBL] [Abstract][Full Text] [Related]
59. Modulation by the polyoxotungstate HPA-23 of Epstein-Barr virus early antigen expression in Raji cells treated with iododeoxyuridine.
Souyri-Caporale M; Tovey MG; Ono K; Jasmin C; Chermann JC
J Gen Virol; 1984 Apr; 65 ( Pt 4)():831-5. PubMed ID: 6323625
[TBL] [Abstract][Full Text] [Related]
60. Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.
Larsen RH; Vaidyanathan G; Zalutsky MR
Int J Radiat Biol; 1997 Jul; 72(1):79-90. PubMed ID: 9246197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
